Publication

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Authors not recorded

Clin Cancer Res2014PMID 24178622PMC4310865stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

cancerAcute Myeloid Leukemiacivic_curation1.00
drugSelumetinibcivic_curation1.00
geneFLT3civic_curation1.00
geneKITcivic_curation1.00
variantFLT3 ITDcivic_curation1.00
variantKIT RS3733542civic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 ITD1
Selumetinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Resistance	2	accepted	EID1137 Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 u… (full text at CIViC) PMID 24178622 · Jain et al., 2014 · Open in CIViC	civic
KIT RS37335421
Selumetinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	1	accepted	EID1136 Patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study of selumetinib and analyzed for mutations in KIT, NRAS, KRAS and FLT3. KIT mutation a… (full text at CIViC) PMID 24178622 · Jain et al., 2014 · Open in CIViC	civic